ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.446,94
-0,03%
S&P 500
6.101,24
-0,29%
US Dollar vs BRL
5,91319
0,00%
Bitcoin
104.591,79
-0,13%
Brent Oil
77,625
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) Notícias

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NBIX
DataHoraFonteTítuloCódigoCompanhia
23/01/202518:05PR Newswire (US)Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and DeviceNASDAQ:NBIXNeurocrine Biosciences Inc
21/01/202518:05PR Newswire (US)Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
17/01/202518:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
15/01/202518:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
08/01/202510:30PR Newswire (US)Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & MetabolismNASDAQ:NBIXNeurocrine Biosciences Inc
06/01/202518:01PR Newswire (US)Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202410:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
20/12/202410:00PR Newswire (US)Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
13/12/202420:55PR Newswire (US)Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal HyperplasiaNASDAQ:NBIXNeurocrine Biosciences Inc
26/11/202418:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in DecemberNASDAQ:NBIXNeurocrine Biosciences Inc
07/11/202410:30PR Newswire (US)Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
05/11/202418:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in NovemberNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202410:30PR Newswire (US)Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
04/11/202410:25PR Newswire (US)Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive DyskinesiaNASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202408:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
30/10/202408:00PR Newswire (US)Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
09/10/202417:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
30/09/202409:30PR Newswire (US)Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic UseNASDAQ:NBIXNeurocrine Biosciences Inc
19/09/202417:01PR Newswire (US)Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual SummitNASDAQ:NBIXNeurocrine Biosciences Inc
12/09/202417:05PR Newswire (US)Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
10/09/202417:01PR Newswire (US)Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
28/08/202417:05PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in SeptemberNASDAQ:NBIXNeurocrine Biosciences Inc
28/08/202408:00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
07/08/202417:01PR Newswire (US)Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
01/08/202411:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NBIXNeurocrine Biosciences Inc
01/08/202408:00PR Newswire (US)Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
18/07/202409:30PR Newswire (US)Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty SwallowingNASDAQ:NBIXNeurocrine Biosciences Inc
11/07/202417:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
01/07/202408:30PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAHNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202409:01PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NBIX

Seu Histórico Recente

ASX
YTMF11
Theta Asset Management
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados